MMG
ENTA icon

Monetary Management Group’s Enanta Pharmaceuticals ENTA Stock Holding History

Monetary Management Group’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-300
Closed -$11K – 324
2015
Q3 		$11K Hold
300
– – 0.01% 316
2015
Q2 		$13K Buy
+300
New +$11.7K 0.01% 322
2015
Q1 		– Sell
-300
Closed -$15K – 362
2014
Q4 		$15K Buy
+300
New +$13.4K 0.01% 332

Other funds holding ENTA

ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Monetary Management Group's ENTA Position: Q4 2015 in Review

Monetary Management Group sold out of Enanta Pharmaceuticals (ENTA) in Q4 2015, closing a stake of 300 shares — an estimated $11K sold.

Monetary Management Group first reported a position in ENTA in Q4 2014 and held it in 3 quarters. The position peaked at $15K in Q4 2014. 136 funds tracked by Wall St. Rank hold ENTA as of Q4 2015.

  • Monetary Management Group reported no remaining Enanta Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Monetary Management Group sold 300 Enanta Pharmaceuticals shares in Q4 2015, an estimated $11K.
  • Monetary Management Group first reported a position in Enanta Pharmaceuticals in Q4 2014 and held it in 3 quarters.
  • Monetary Management Group's Enanta Pharmaceuticals position peaked at $15K in Q4 2014.
  • 136 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2015.

Based on Monetary Management Group's 13F filing for Q4 2015, filed 11 Feb 2016.